Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Acorda Therapeutics, a biotechnology company, has resubmitted its new drug application for Fampridine-SR to the FDA. Fampridine-SR is a novel therapy being developed to improve walking ability in people with multiple sclerosis.
Subscribe to our email newsletter
Acorda received a refuse to file (RTF) letter for the Fampridine-SR new drug application (NDA) on March 30, 2009, which cited the need to correct ‘format issues’ and requested additional supporting information before the NDA could be accepted for review.
Based on subsequent discussions with the FDA, Acorda has resubmitted the Fampridine-SR NDA and believes that all of the agency’s comments related to the RTF have been addressed.